Last €42.62 EUR
Change Today +0.383 / 0.91%
Volume 4.3K
MDT On Other Exchanges
Symbol
Exchange
Mexico
Frankfurt
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT) Snapshot

Open
€42.10
Previous Close
€42.24
Day High
€42.77
Day Low
€41.94
52 Week High
04/4/14 - €46.08
52 Week Low
04/30/13 - €35.00
Market Cap
42.7B
Average Volume 10 Days
7.9K
EPS TTM
--
Shares Outstanding
1.0B
EX-Date
04/2/14
P/E TM
--
Dividend
€1.12
Dividend Yield
1.95%
Current Stock Chart for MEDTRONIC INC (MDT)

medtronic inc (MDT) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. The Cardiac and Vascular Group’s products include pacemakers; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management (CRDM) devices; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery devices for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder (OCD), overactive bladder, urinary retention, and fecal incontinence and gastroparesis; external insulin pumps; subcutaneous CGM systems; products to treat conditions of the ear, nose, and throat; and devices that incorporate advanced energy technology. It also manufactures and sells image-guided surgery and intra-operative imaging systems; and provides Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

46,659 Employees
Last Reported Date: 06/24/13
Founded in 1949

medtronic inc (MDT) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $716.5K
Executive Vice President and Group President ...
Total Annual Compensation: $670.2K
Executive Vice President and Group President ...
Total Annual Compensation: $630.2K
Compensation as of Fiscal Year 2013.

medtronic inc (MDT) Key Developments

Medtronic, Inc. Announces CE Mark and European Launch of Evera MRI Surescan Implantable Cardioverter-Defibrillator System

Medtronic, Inc. announced CE mark and European launch of the Evera MRI SureScan implantable cardioverter-defibrillator, or ICD, System, an ICD system approved for magnetic resonance imaging, or MRI, scans positioned on any region of the body. The Evera MRI maintains the same battery longevity (up to 11 years) compared to previous devices. In addition, Evera MRI is paired with the Sprint Quattro Secure family of ICD leads, which has 10 years of proven performance with active monitoring and is safe for use in an MRI environment. Evera MRI includes SmartShock 2.0 - an exclusive shock reduction algorithm that enables the device to better differentiate between dangerous and harmless heart rhythms. While the majority of shocks delivered are necessary to treat potentially fatal arrhythmias, studies estimate that approximately 20% of patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device. SmartShock technology helps to eliminate these inappropriate shocks, and delivers a 98% inappropriate shock free rate at one year. Also included in the Evera MRI is OptiVol 2.0 Fluid Status Monitoring and complete diagnostics, which helps to identify patients at risk of worsening heart failure and atrial fibrillation.

Federal Court Orders Preliminary Injunction on U.S. Sales of Medtronic's Infringing Transcatheter Valve

Edwards Lifesciences Corporation announced that the U.S. District Court for the District of Delaware granted a preliminary injunction limiting the sale of Medtronic's CoreValve system in the United States. The court ordered the injunction to go into effect in seven business days. The hearing related to a federal jury decision in 2010 that CoreValve willfully infringes Edwards' U.S. Andersen transcatheter aortic valve replacement patent. At the conclusion of the hearing, Chief Judge Gregory Sleet ordered Edwards and Medtronic to confer on what instances the CoreValve device could continue to be used in the treatment of U.S. patients at centers currently trained on CoreValve. There is a large body of evidence demonstrating the safety and performance of the Edwards SAPIEN valves, and the company remains committed to ensuring patients have appropriate access to transcatheter therapy.

Medtronic CRT Devices Now Approves to Treat Patients with AV Block and Reduced Heart Function

Medtronic, Inc. announced that the U.S. Food and Drug Administration approved an expanded indication for biventricular pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators. Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricular (LV) systolic dysfunction, reducing heart failure hospitalizations and mortality, and improving cardiac function in these patients. The expanded indication allows patients designated as New York Heart Association Class I, II and III with AV block that are expected to require a high percentage of ventricular pacing, and who have an ejection fraction (measure of the heart's pumping ability) less than or equal to 50%, to receive BiV pacing via Medtronic CRT devices. The FDA's approval was based on the landmark BLOCK HF clinical trial, which demonstrated significant clinical advantages of BiV pacing compared with traditional right ventricular (RV) pacing in this patient population, including a 27% relative risk reduction in the composite study endpoint of heart size, heart failure hospitalizations and mortality.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:GR €42.62 EUR +0.383

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $38.93 USD +0.55
Allergan Inc/United States $133.92 USD +2.46
Baxter International Inc $72.81 USD -0.64
Covidien PLC $69.86 USD +0.02
Stryker Corp $78.78 USD -0.27
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 16.6x
Price/Sales 3.5x
Price/Book 3.0x
Price/Cash Flow 14.9x
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.